Next Phase Newsletter

An active early stage venture fund with offices in Western Europe is led by a team composed of experienced professionals in funding, entrepreneurship and therapeutic development. Currently, the firm’s investment focus is in cell and gene therapy and their manufacturing technologies.

The firm is especially interested in companies developing therapeutic approaches, such as state of the art cell therapies in regenerative and autoimmune fields that need local manufacturing. The firm is primarily interested in early stage, pre-clinical breakthrough technologies seeking seed investment.

The firm takes an active role with the companies in which they invest. The firm frequently leads rounds, and supports and mentors the early stage companies, often either taking a board seat themselves or finding an expert to serve on the board. Apart of building companies, Delin Ventures is also interested in the investment in the existing companies, syndicating with other investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm based in the US is seeking opportunities in the medical devices, diagnostics, and digital health sectors of life sciences. The firm is looking to engage in Series A to Series B financing rounds with check sizes between 5 – 10 million USD. The firm prefers to lead the financing rounds but is open to co-investing. The firm will consider opportunities globally.

The firm is interested in early-stage opportunities in medical devices, diagnostics, and digital health sectors but does not invest in therapeutics. The firm is overall opportunistic and will consider various subsectors and indications. For digital health, the firm prefers b-to-b over b-to-c products. The firm will invest in all early-stage companies including pre and post commercial enterprises.

The firm seeks to work with management teams that have prior entrepreneurial experience. The firm prefers to lead financing rounds and will most likely take a board seat when leading. The firm considers themselves an active investor and will work closely with companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture fund founded and headquartered in the US invests in early-stage companies that focus on reproductive and maternal health typically in Seed and Series A. The fund is impact focused to improve accessibility, affordability, innovation, and systemic change within women’s health. Typical check size is about $1M for the initial round and up to $3M across company lifespan. The firm will both lead and co-invest in global companies.

The firm invests across all healthcare segments: therapeutics, digital health, devices, diagnostics, etc. from pre-clinical to clinical stages as it relates to reproductive and maternal health.

The firm does not have specific management team requirements. The firm may take a board seat depending on the case. The firm would at least like to take an observer seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A a life science specialist venture fund manager with offices in Europe and Asia has multiple billion dollars of assets under management. The firm invests in preclinical to clinical-stage life science companies, primarily in the field of therapeutic drug development with products addressing high unmet medical need and complementing Pharma’s pipelines. The firm deploys its capital with a geographic focus on Europe (~2/3 of investments) and North America (~1/3 of investments). Currently, the firm invests out of two new funds: one of them is focusing on preclinical to early clinical-stage assets; and the other one is focusing on private growth capital, cross-over/IPO rounds and PIPE investments in clinical-stage companies. The typical investment per round is €35-50M for both funds.

The firm invests in preclinical to clinical-stage life science companies, primarily in the field of therapeutic drug development with products addressing high unmet medical need and complementing Pharma’s pipelines.

The firm seeks a company with a strong and experienced management team and/or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A strategic venture firm backed by a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere, focuses on early and growth stage digital health and tech-enabled healthcare services companies. Initial allocations are typically from $5-10 million with the possibility of follow-on investments up to $25 million.

The firm focuses on five areas of innovation in healthcare – pharma clinical and commercial services, data and analytics, oncology, pharmacy services, and new care models.

The firm is equally focused on financial returns and ways the firm can potentially contribute value beyond the capital investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm headquartered in Western Europe focuses on deeptech, specifically covering their thesis of transformative and frontier technology – technical solutions that can vastly change and command a huge market. The firm invests in Pre-Seed and Seed stage companies. Typical check size is a fixed amount of $500k USD, and the firm can act both as a lead or co-investor. The firm is geographically agnostic, but has made most of its investments in Europe and the USA.

In terms of life science, the firm considers digital health and sometimes device or diagnostic companies that have an AI component or some sort of consumer facing platform. The firm can go as early as the pre-revenue concept stage, right through to those with a sustained record of aggressive growth.

The firm does not have management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A women-led venture capital firm headquartered in the US is led by a team that brings together expertise in both healthcare and venture capital and can help build industry-transforming companies with exponential impact and returns. The firm is currently investing from their first fund in Seed to Series B technology start-ups that address healthcare problems such as uncured and unmanaged disease, lack of access to care, poor quality and medical errors, health disparities, and unsustainable costs. The firm is open to global companies as 20% of the fund is invested internationally. The firm both co-invests and leads rounds with initial check sizes ranging from $250k-2.5M.

The firm invests in diagnosis, delivery of care (digital health), and technologies to enable drug discovery and development with the underlying thesis of data and AI. The firm does not invest in traditional pharma or therapeutics companies. The firm is indication-agnostic. Typically, the firm invests in companies generating revenue but is open to investing pre-revenue for particularly compelling technologies.

The firm often requires taking an observer or board seat. The firm does not have specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.